Medtronic is the predominant player in the energy-based therapies market. With global sales of nearly $4.9 billion attributable to energy-based products, it controls over half of the cardiac rhythm market and almost a quarter of all energy-based product sales. Boston Scientific, also focusing on cardiac arrhythmias, comes next in the revenues table with a [...]
bookmark to
